The online version of this article (doi:10.1186/1752-1947-8-443) contains supplementary material, which is available to authorized users.
C Romano, C Tamburella, M Costa, M Messina and AL Fassari declare that they have no competing interests.
Marco Bertini has competing interests because he is the Medical Department Director of Laboratori Baldacci, the company that produces aminaphtone.
CR, CT, MC and MM clinically followed the patient during his hospitalisation time; CR performed videocapillaroscopy examination; ALF followed the time course of the retinal complications of the patient; MB conceived of the study, collected the data and helped to draft the manuscript. All authors read and approved the final manuscript.
Microalbuminuria in type 1 diabetes is the earliest manifestation of diabetic microangiopathy (nephropathy). To date, the pharmacological approach to microangiopathy has not been shown to be useful. By using aminaphtone to control nephrologic complications of insulin-dependent diabetes mellitus we first obtained a significant improvement in microalbuminuria confirming this new pharmacological approach for insulin-dependent diabetes mellitus organospecific complications control.
After being treated with standard therapy for insulin-dependent diabetes mellitus (insulin) for more than 20 years, a 49-year-old white man affected by insulin-dependent diabetes mellitus adopted the standard therapy aminaphtone for a period of 2 months.
This therapy allowed a significant reduction of proteinuria from baseline evaluation that immediately increased after he stopped aminaphtone therapy.
Aminaphtone therapy, used globally in the treatment and prevention of endothelial dysfunctions, could be an interesting option for patients with insulin-dependent diabetes mellitus with the express purpose of preventing diabetic nephropathy.
Viberti GC, Hill RD, Jarrett RJ, Argyropoulos A, Mahmud U, Keen H: Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus. Lancet. 1982, i: 1430-1432. CrossRef
Ritz E: Nephropaty in type 2 diabetes. J Int Med. 1999, 245: 111-126. 10.1046/j.1365-2796.1999.00411.x. CrossRef
Alzaid AA: Microalbuminuria in patients with NIDDM: an overview (Review). Diabetes Care. 1996, 19: 69-89. CrossRef
American Diabetes Association: Diabetic nephropathy (Position Statement). Diabetes Care. 2000, 23 (Suppl. 1): S29-S72.
The Microalbuminuria Collaborative Study Group: Predictors of the development of microalbuminuria in patients with type 1 diabetes mellitus: a seven-year prospective study. Diabet Med. 1999, 16: 918-925. 10.1046/j.1464-5491.1999.00182.x. CrossRef
Villar G, Garcia Y, Goicolea I, Vasquez JA: Determinants of development of microalbuminuria in normotensive patients with type 1 and type 2 diabetes. Diabet Metab. 1999, 25: 246-254.
Olgemoller B, Schleicher E: Alterations of glomerular proteins in the pathogenesis of diabetic nephropathy. Clin Invest. 1993, 71: S13-S19. 10.1007/BF00210957. CrossRef
Atenas JG: The efficacy of aminaphtone in patients suffering from chronic venous insufficiency. Ann Exp Clin Med. 1995, 2: 81-85.
Scorza R, Santaniello A, Salazar G, Lenna S, Colombo G, Turcatti F, Beretta L: Aminaftone, a derivative of 4-aminobenzoic acid, downregulates endothelin-1 production in ECV304 Cells: an in vitro Study. Drugs RD. 2008, 9 (4): 251-257. 10.2165/00126839-200809040-00005. CrossRef
Lenna S, Salazar G, Della Bella S, Antonioli R, Beretta L, Santaniello A, Scorza R: Novel Mode of Action of The Aminaphtone: Down-Regulation of E-Selectin expression in ECV304 Cells. 2006, Lisbon (Portugal): Abstract Book of the XXII World Congress of the International Union of Angiology
Scorza R, Santaniello A, Salazar G, Lenna S, Della Bella S, Antonioli R, Toussoun K, Beretta L: Effects of aminaftone 75mg TID on soluble adhesion molecules: a 12-week, randomized, open label pilot study in patients with systemic sclerosis. Clin Ther. 2008, 30 (5): 924-929. 10.1016/j.clinthera.2008.05.009. CrossRefPubMed
Scorza R, Salazar G, Bellocchi C: Aminaftone: un possibile ruolo nella sclerosi sistemica?. Gruppo Italiano per la Lotta alla Sclerodermia (GILS). Rubrica Medica – Giugno 2013
- Aminaphtone therapy in patients with type 1 diabetes and albuminuria: a case report
Anna Lisa Fassari
- BioMed Central